CVS Warns of 2027 Caremark Membership Decline, 340B Pressures Despite Q2 Beat
CVS sits 60% above its 52-week low of $61.35.
Summary
CVS shares fell 6% despite a massive Q2 beat and raised 2026 guidance, as the company issued early warnings about 2027 headwinds. Caremark PBM membership will decline next year due to contract rewrites for a new pricing model and insurer pullbacks. The company also flagged 340B drug-discount program pressures. Management called the current 2027 consensus EPS a reasonable floor and reaffirmed mid-teens earnings growth through 2028. This follows the Q2 8-K and earnings release earlier today, adding forward-looking caution that undercuts the strong quarter. The PBM warning is particularly notable given ongoing regulatory scrutiny and the recent FTC settlement with Caremark.
At the time of this announcement, CVS was trading at $98.19 on NYSE in the Trade & Services sector, with a market capitalization of approximately $125.3B. The 52-week trading range was $61.35 to $110.68. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.